Nov 29, 2021 / 01:30PM GMT
Operator
Good morning. My name is Juan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines Conference Call. (Operator Instructions)
I would like now to introduce to your host, Kristin Hodous from Blueprint. Kristin, please, you may begin your conference.
Kristin Hodous - Blueprint Medicines Corporation - Senior Manager of IR
Thank you, operator. Good morning, everyone, and welcome to Blueprint Medicines conference call to discuss our planned acquisition of Lengo Therapeutics. This morning, we issued a press release announcing the transaction, which we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing by going to the Investors section of our website, at www.blueprintmedicines.com.
Joining us today on our call are Jeff Albers, our Chief Executive Officer; Keith Haviland, our Chief Operating Officer; and Fouad Namouni, our President of Research and Development;
Blueprint Medicines Corp to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics Inc Call Transcript
Nov 29, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers